We are Sorry, This Page doesn't Exist
Bristol-Myers Squibb stock falls on lung cancer drug study result
Bristol-Myers Squ.....»»
AbbVie Halts Rova-T Phase III Second-Line Lung Cancer Study
IDMC recommends AbbVie (ABBV) to stop enrolment in a.....»»
Merck stock slides as lung-cancer drug misses a study endpoint
Merck & Co. shares slipped in the extended session Monday after the drug maker said that its lung-cancer drug Keytruda did not meet one of its endpoints in a clinical study. Merck shares declined 0......»»
OncoCyte (OCX) Stock Skyrockets on Lung Cancer Test Study Results
InvestorPlace - Stock Market News, Stock Advice & Tradi.....»»
Merck stock falls in late trading on cancer study
Merck & Co. In.....»»
Rare Disease-Focused-Ultragenyx Pharmaceutical Stock Falls On Serious Adverse Events In Eaarly Genetic Disorder Study
New data from Phase 1/2 study of GTX-102 for Angelman syndrome shows rapid and sustained improvement in patients, exceeding natural history data. read more.....»»
Myovant"s stock falls after FDA puts partial clinical hold on trial for contraceptive candidate
Shares of Myovant Sciences Ltd. were down 5.7% in premarket trading on Wednesday after the company told investors that the Food and Drug Administration had placed a partial clinical hold on a study assessing an experimental birth c.....»»
Abbvie (ABBV) Dividend Stock Analysis for 2021
AbbVie Inc. (ABBV) discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company was created in 2013, when Abbott Laboratories split into two companies – Abbvie and Abbott. Abbvie.....»»
"Halftime Report" Traders Weigh In On AbbVie, Chewy And More
On CNBC's "Fast Money Halftime Report," Jim Cramer advised a viewer to stay long in AbbVie Inc (NYSE: ABBV). He loves the stock and the yield. read more.....»»
AbbVie Stock Is Estimated To Be Fairly Valued
Related Stocks: ABBV,.....»»
Karyopharm Stock Is Trading Higher After China"s NMPA Signs Off Early-Stage ATG-019 Study In Cancer Settings
read more.....»»
Why AbbVie"s Stock is Trading Lower Today
The Price And Volume Action In AbbVie's Stock Today AbbVie (NYSE:ABBV) is currently down 5.54% to a price of $104.49. The stock's volume is currently 6.90 million, which is roughly 99.43% of its recent 30-day volume average of 6.94 million. read more.....»»
Sorrento Developed Socazolimab Enters Late-Stage Lung Cancer Study In China
China's regulatory authorities have signed off on Lee's read more.....»»
Heat Biologics stock more than doubles after "positive" trial data of its lung cancer treatment
Shares of Heat Biologics Inc. more than doubled in very active trading Tuesday, after the biopharmaceutical company focused on modulating the immune system reported "positive" in.....»»
Heat Biologics Cell Therapy Shows Survival Benefit In Mid-Stage Lung Cancer Study, Shares Rally
read more.....»»
Unusual Options Activity Insight: AbbVie
AbbVie (NYSE:ABBV) shares experienced unusual options activity on Wednesday. The stock price moved up to $103.37 following the option alert. read more.....»»
Biodesix begins biomarker study of Nodify XL2 lung cancer test
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Veru"s stock soars again on heavy volume after positive results of breast cancer treatment
Shares of Veru Inc. soared 51.4% toward a seven-year high on massive volume, after the biopharmaceutical company announced positive results from a Phase 2 study of its treatment.....»»
Cassava stock falls on failed Alzheimer"s study
Shares of Cassava Sciences Inc. tumbled 73.2% in trading on Friday after the company said its investigational Alzheimer's disease treatment failed a mid-.....»»